Ubs Group Ag Vincerx Pharma, Inc. Call Options Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding VINC
# of Institutions
28Shares Held
11MCall Options Held
0Put Options Held
0-
Armistice Capital, LLC New York, NY2.7MShares$838,2400.03% of portfolio
-
Prosight Management, LP Dallas, TX2.21MShares$684,0160.43% of portfolio
-
Sage Rhino Capital LLC1.7MShares$528,0580.28% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD892KShares$276,4320.02% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct674KShares$208,9990.0% of portfolio
About Vincerx Pharma, Inc.
- Ticker VINC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,189,800
- Market Cap $6.57M
- Description
- Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candid...